Aliases & Classifications for Impotence

Aliases & Descriptions for Impotence:

Name: Impotence 12 29 52 14
Erectile Dysfunction 12 52 41 14 69
Erectile Dysfunction Adverse Event 69
Sexual Impotence 12

Classifications:



External Ids:

Disease Ontology 12 DOID:1875

Summaries for Impotence

MedlinePlus : 41 erectile dysfunction (ed) is a common type of male sexual dysfunction. it is when a man has trouble getting or keeping an erection. ed becomes more common as you get older. but it's not a natural part of aging. some people have trouble speaking with their doctors about sex. but if you have ed, you should tell your doctor. ed can be a sign of health problems. it may mean your blood vessels are clogged. it may mean you have nerve damage from diabetes. if you don't see your doctor, these problems will go untreated. your doctor can offer several new treatments for ed. for many men, the answer is as simple as taking a pill. getting more exercise, losing weight, or stopping smoking may also help. nih: national institute of diabetes and digestive and kidney diseases

MalaCards based summary : Impotence, also known as erectile dysfunction, is related to vasculogenic impotence and diabetic neuropathy, and has symptoms including angina pectoris, pelvic pain and tremor. An important gene associated with Impotence is NOS1 (Nitric Oxide Synthase 1), and among its related pathways/superpathways are Response to elevated platelet cytosolic Ca2+ and G-Beta Gamma Signaling. The drugs Methyltestosterone and Testosterone have been mentioned in the context of this disorder. Affiliated tissues include kidney, brain and prostate, and related phenotypes are endocrine/exocrine gland and renal/urinary system

Wikipedia : 71 Erectile dysfunction (ED), also known as impotence, is a type of sexual dysfunction characterized by the... more...

Related Diseases for Impotence

Diseases related to Impotence via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 104)
id Related Disease Score Top Affiliating Genes
1 vasculogenic impotence 12.1
2 diabetic neuropathy 11.1
3 autonomic dysfunction 10.7
4 dysautonomia 10.7
5 multiple system atrophy 10.7
6 multiple system atrophy with orthostatic hypotension 10.7
7 amyloidosis, hereditary, transthyretin-related 10.7
8 dysautonomia, familial 10.7
9 empty sella syndrome 10.7
10 7q11.23 duplication syndrome 10.3 NOS1 NOS3 PRL
11 proliferating trichilemmal cyst 10.2 EDN1 NOS3
12 gastroduodenal crohn's disease 10.2 ALDH7A1 NOS1 NOS3
13 glioblastoma mesenchymal subtype 10.2 KLK3 PRL SHBG
14 diabetic macular edema 10.2 NOS1 NOS2 VIP
15 capillary disease 10.2 KLK3 PRL SHBG
16 renovascular hypertension 10.2 EDN1 NOS1 NOS3
17 indeterminate leprosy 10.2 EDN1 KNG1 NOS3
18 necrobiosis lipoidica 10.1 KLK3 PRL SHBG
19 traumatic glaucoma 10.1 EDN1 NOS3 PDE5A
20 cone-rod dystrophy 3 10.1 ALDH7A1 KCNMA1
21 prostatitis 10.1
22 avoidant personality disorder 10.1 KLK3 PRL SHBG
23 poikiloderma with neutropenia 10.1 EDN1 NOS2 NOS3
24 zellweger syndrome 10.1 EDN1 NOS2 NOS3
25 kartagener syndrome 10.1 ACE NOS3 PDE5A
26 hypothyroidism, congenital nongoitrous, 5 10.1 ACE KCNMA1
27 retroperitoneal sarcoma 10.1 NOS2 NOS3 PRL SHBG
28 hepatic infarction 10.1 EDN1 KNG1
29 villous adenoma 10.1 ACE NOS3 PDE5A
30 prostate cancer 10.0
31 petrositis 10.0 ACE EDN1 KNG1
32 aplasia cutis congenita recessive 10.0 ACE EDN1 NOS3
33 lymphadenitis 10.0 ACE EDN1 NOS3
34 acute posterior multifocal placoid pigment epitheliopathy 10.0 ACE EDN1 NOS3
35 oppositional defiant disorder 10.0 ACE EDN1 NOS3
36 testicular lymphoma 10.0 ACE EDN1 PRL
37 dystonia-parkinsonism, x-linked 10.0 SHBG SRD5A1
38 limb ischemia 10.0 ACE EDN1 NOS3
39 urethritis 10.0
40 peyronie's disease 10.0
41 infertility 10.0
42 diabetic encephalopathy 10.0 ACE EDN1 NOS3
43 body dysmorphic disorder 10.0 ACE NOS3 PRL SHBG
44 alpha-2-plasmin inhibitor deficiency 9.9 ACE EDN1 NOS3 PDE5A
45 calcinosis 9.9 ACE EDN1 KLK3
46 iris disease 9.9 ACE NOS3
47 pyrimidine metabolic disorder 9.9 ACE EDN1 KNG1 NOS3
48 pyelonephritis 9.9 ACE EDN1 NOS2 NOS3
49 critical limb ischemia 9.9 ACE EDN1 KNG1
50 macular degeneration, age-related, 12 9.9 ACE EDN1 KNG1 NOS3

Graphical network of the top 20 diseases related to Impotence:



Diseases related to Impotence

Symptoms & Phenotypes for Impotence

UMLS symptoms related to Impotence:


angina pectoris, pelvic pain, tremor, symptom/complaint potency (excluding p07 p08), equilibration disorder, inability to maintain erection, unable to perform sex

MGI Mouse Phenotypes related to Impotence:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 9.81 CAV1 EDN1 NOS1 NOS2 NOS3 PRL
2 renal/urinary system MP:0005367 9.5 ACE CAV1 EDN1 KCNMA1 NOS1 NOS2
3 reproductive system MP:0005389 9.32 ACE CAV1 KCNMA1 NOS1 NOS2 NOS3

Drugs & Therapeutics for Impotence

Drugs for Impotence (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 273)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Methyltestosterone Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 58-18-4 6010
2
Testosterone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 58-22-0 6013
3
Benzocaine Approved Phase 4,Phase 3 1994-09-7, 94-09-7 2337
4
Nebivolol Approved, Investigational Phase 4 152520-56-4, 99200-09-6, 118457-14-0 71301
5
Tadalafil Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 171596-29-5 110635
6
Felodipine Approved, Investigational Phase 4 72509-76-3 3333
7
Irbesartan Approved, Investigational Phase 4 138402-11-6 3749
8
Metoprolol Approved, Investigational Phase 4 37350-58-6, 51384-51-1 4171
9
Dutasteride Approved, Investigational Phase 4,Phase 3,Phase 2 164656-23-9 152945 6918296
10
Alprostadil Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 745-65-3 149351
11
Nitric Oxide Approved Phase 4,Phase 2 10102-43-9 145068
12
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492
13
Udenafil Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 268203-93-6 6918523
14
Zinc Approved Phase 4 7440-66-6 32051 23994
15
Yohimbine Approved, Vet_approved Phase 4 146-48-5 8969
16
Hydrochlorothiazide Approved, Vet_approved Phase 4 58-93-5 3639
17
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
18
Magnesium oxide Approved Phase 4 1309-48-4 14792
19
Tiagabine Approved Phase 4 115103-54-3 60648
20
Eszopiclone Approved Phase 4 138729-47-2 969472
21
Tamsulosin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 106133-20-4 129211
22
Dopamine Approved Phase 4,Phase 2 51-61-6, 62-31-7 681
23
Ropinirole Approved, Investigational Phase 4 91374-20-8, 91374-21-9 5095 497540
24
Rosiglitazone Approved, Investigational Phase 4,Phase 1 122320-73-4 77999
25
Selegiline Approved, Investigational, Vet_approved Phase 4 14611-51-9 26757 5195
26
Fenofibrate Approved Phase 4 49562-28-9 3339
27
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
28 tannic acid Approved, Nutraceutical Phase 4,Phase 3
29
Ergocalciferol Approved, Nutraceutical Phase 4 50-14-6 5280793
30
N,N-dimethylarginine Experimental Phase 4 30315-93-6 123831
31 Anabolic Agents Phase 4,Phase 3,Phase 2,Early Phase 1
32 Androgens Phase 4,Phase 3,Phase 2,Early Phase 1
33 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Early Phase 1
34 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
35 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
36 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
37 Testosterone 17 beta-cypionate Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
38
Testosterone enanthate Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 315-37-7 9416
39 Testosterone undecanoate Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
40 Vardenafil Dihydrochloride Phase 4,Phase 3,Phase 2,Phase 1
41 Phosphodiesterase 5 Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
42 Phosphodiesterase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
43 Vasodilator Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
44 Adrenergic Agents Phase 4,Phase 3,Phase 2,Phase 1
45 Adrenergic Agonists Phase 4,Phase 1,Phase 2
46 Adrenergic beta-Agonists Phase 4,Phase 1,Phase 2
47 Antihypertensive Agents Phase 4,Phase 3,Phase 2,Phase 1
48 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1
49 Hypoglycemic Agents Phase 4,Phase 3,Phase 2,Phase 1
50 insulin Phase 4,Phase 3,Phase 1

Interventional clinical trials:

(show top 50) (show all 491)
id Name Status NCT ID Phase
1 Treatment of Erectile Dysfunction in Hypogonadal Men With Testosterone Undecanoate Unknown status NCT00555087 Phase 4
2 A Study to Evaluate the Efficacy and Safety of Vardenafil in Men With Erectile Dysfunction Caused by Spinal Cord Injury Unknown status NCT00725790 Phase 4
3 Nebivolol Effects on Endothelial Function and Erectile Function Unknown status NCT01885988 Phase 4
4 The Incidence and Treatment of Insulin Resistance Among Men With Erectile Dysfunction Unknown status NCT00284960 Phase 4
5 Evaluation of Safety and Effectiveness of 2 Lower Dose Combined PDE5i's Versus Single Maximal Dose PDE5i Treatment Unknown status NCT01364701 Phase 4
6 Effect of Sildenafil on Quality of Sexual Life in Mild to Normally Sexually Functioning Males Unknown status NCT00313898 Phase 4
7 Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer Unknown status NCT00906269 Phase 4
8 Safety and Clinical Effectiveness of 2 Lower Dose Combined PDE5i's vs. Single Maximal Dose PDE5i Unknown status NCT00498680 Phase 4
9 Effect of Testosterone on Endothelial Function and Microcirculation in Type 2 Diabetic Patients With Hypogonadism Unknown status NCT01084369 Phase 4
10 Combined Antihypertensive Therapy and Sexual Dysfunction Unknown status NCT01238705 Phase 4
11 A Study in Patients With Erectile Dysfunction Completed NCT01122264 Phase 4
12 L-Arginine and Erectile Dysfunction Completed NCT00777075 Phase 4
13 Evaluation of LEVITRA to Advance the Treatment of Erectile Dysfunction Completed NCT00664833 Phase 4
14 Evaluating of the Efficacy and Safety of Vardenafil in Subjects With Erectile Dysfunction Completed NCT00662441 Phase 4
15 Assessment of Vardenafil in Patients With Erectile Dysfunction in Asia Completed NCT00668135 Phase 4
16 Investigate the Responsiveness of the Erectile Quality Scale to Vardenafil Flexible Dose vs Placebo in Males With Erectile Dysfunction (ED) Completed NCT00665340 Phase 4
17 Evaluation of the Safety and Efficacy of Vardenafil in Subjects With Erectile Dysfunction Completed NCT00681772 Phase 4
18 Vardenafil and Cognitive-behavioral Sex Therapy for the Treatment of Erectile Dysfunction (STEDOV) Completed NCT02450188 Phase 4
19 Effect of Tadalafil on the Quality of Life and Sexual Life in Erectile Dysfunction Completed NCT00422578 Phase 4
20 Assessing Efficacy and Safety of Flexible Dosing With Vardenafil in Subjects With Erectile Dysfunction and Hyperlipidemia Completed NCT00663845 Phase 4
21 BAY38-9456, 5/10/20mg, vs.Placebo in Erectile Dysfunction Completed NCT00665054 Phase 4
22 Efficacy and Safety of Lodenafil Carbonate in the Treatment of Erectile Dysfunction in Patients With Diabetes. Completed NCT01180283 Phase 4
23 Satisfaction, Confidence and Naturalness in Men With Psychogenic Erectile Dysfunction (ED) Completed NCT01153204 Phase 4
24 Impact Of Viagra On Sexual Satisfaction Of Men With Mild Erectile Dysfunction Who Are Sexually Dissatisfied Completed NCT00301262 Phase 4
25 Evaluation of Efficacy and Safety of Vardenafil in Patients With Erectile Dysfunction and Type 1 Diabetes Completed NCT00660998 Phase 4
26 A Study of Tadalafil and Sildenafil in Men With Erectile Dysfunction in China Completed NCT01352507 Phase 4
27 The Therapy of Nebido as Mono or in Combination With PDE-5 Inhibitors in Hypogonadal Patients With Erectile Dysfunction Completed NCT00421460 Phase 4
28 Research Evaluating a PDE5 Inhibitor for Erectile Dysfunction Completed NCT01698684 Phase 4
29 A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy Completed NCT00106392 Phase 4
30 Evaluating the Efficacy Vardenafil 10 mg vs Tadalafil 10 mg in in Subjects With Erectile Dysfunction (ED) Completed NCT00663130 Phase 4
31 A Multicenter, Open Label, To Evaluate The Efficacy And Satisfaction Of Patrex® In Men With Erectile Dysfunction. Completed NCT00468650 Phase 4
32 A Study Evaluating Vardenafil Compared to Placebo in Subjects With Erectile Dysfunction (ED) and Dyslipidemia Completed NCT00379756 Phase 4
33 A Multicenter, Randomized, Parallel Group, Double-Blind, Placebo Controlled, Flexible Dose Escalation Study To Evaluate Sexual And Relationship Satisfaction In The Female Partner Of Men With Erectile Dysfunction Treated With Sildenafil Citrate Completed NCT00644631 Phase 4
34 Study of Vardenafil in Patients Suffering From Erectile Dysfunction and Metabolic Syndrome Completed NCT00738400 Phase 4
35 Effect of Testosterone in Men With Erectile Dysfunction Completed NCT00512707 Phase 4
36 A Randomized, Open-Label, Crossover, Multicenter, Single Dose Comparator Study Evaluating Onset Of Penile Rigidity In Men With Erectile Dysfunction Who Are Treated With Sildenafil And Tadalafil Completed NCT00644956 Phase 4
37 A Study Evaluating the Efficacy and Safety of Sildenafil in Patients With Erectile Dysfunction Receiving Hemodialysis Completed NCT00654017 Phase 4
38 A Study Of The Evaluation Of Patients Opulation With Erectile Dysfunction, Treated With Sildenafil Completed NCT01108900 Phase 4
39 Exploratory CSII Trial on Erectile Dysfunction in T2DM Patients Completed NCT01468519 Phase 4
40 Mild To Moderate Erectile Dysfunction Study Completed NCT00137072 Phase 4
41 Study Of Men With Mild To Moderate Erectile Dysfunction To Evaluate The Efficacy Of Viagra 8 Hours Post-Dose Completed NCT00143260 Phase 4
42 Evaluating the Efficacy of Vardenafil in Subjects With Erectile Dysfunction (ED) Administered 12, 18 or 24 Hours Prior to Intercourse Completed NCT00667979 Phase 4
43 A Randomised Study of Levitra to Treat Men With Erections Problems and Previously Untreated With Similar Therapy. Completed NCT00668096 Phase 4
44 Use of Sildenafil (Viagra) in Diabetic Men With Erectile Dysfunction: the Impact on Blood Vessels Completed NCT00199563 Phase 4
45 Quality of Erection Study Completed NCT00159900 Phase 4
46 A Multicenter, Double-Blind Study to Evaluate the Effect of Pretreatment With a Daily Dose of Sildenafil on the As-Needed Efficacy of Viagra in Men With Erectile Dysfunction and Type 2 Diabetes Completed NCT00645268 Phase 4
47 The Efficacy and Safety of New Herbal Formula (KBMSI-2) in the Treatment of Erectile Dysfunction Completed NCT02413099 Phase 4
48 A Study in Erectile Dysfunction Completed NCT00833638 Phase 4
49 A Study of Visual Effects of Erectile Dysfunction Medications Dosed Daily for Six Months Completed NCT00333281 Phase 4
50 Efficacy Study Measuring The Impact Of Treatment With Viagra On The Depressive Symptoms Of Men With Erectile Dysfunction Completed NCT00159809 Phase 4

Search NIH Clinical Center for Impotence

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Genetic Tests for Impotence

Genetic tests related to Impotence:

id Genetic test Affiliating Genes
1 Impotence 29

Anatomical Context for Impotence

MalaCards organs/tissues related to Impotence:

39
Kidney, Brain, Prostate, Testes, Endothelial, Smooth Muscle, Spinal Cord

Publications for Impotence

Articles related to Impotence:

(show top 50) (show all 577)
id Title Authors Year
1
Impotence Following Radical Prostatectomy: Insight into Etiology and Prevention. ( 28012765 )
2017
2
Impotence after Radical Prostatectomy. ( 28010984 )
2017
3
Omnipotence and Impotence: The Need for Conversation When Patients and Clinicians Disagree. ( 27366844 )
2016
4
Quality analysis of randomized controlled trials in the International Journal of Impotence Research: quality assessment and relevant clinical impact. ( 27904149 )
2016
5
At a Loss for Words: Nosological Impotence in the Search for Justice. ( 26944742 )
2016
6
Baseline status and dose to the penile bulb predict impotence 1A year after radiotherapy for prostate cancer. ( 27079673 )
2016
7
Infertility, impotence, and emasculation - psychosocial contexts for abandoning reproduction. ( 26924280 )
2016
8
Half a Man: The Symbolism and Science of Paraplegic Impotence in World War II America. ( 27066626 )
2015
9
Does impotence improve afterA parathyroidectomy in men withA primary hyperparathyroidism? ( 26492988 )
2015
10
Impotence: a frustratingly elusive target. ( 24857943 )
2014
11
Alprostadil for the treatment of impotence. ( 24369066 )
2014
12
Impotence due to external iliac steal syndrome: treatment with percutaneous transluminal angioplasty and stent placement. ( 23323034 )
2013
13
Endovascular embolisation therapy in men with erectile impotence due to veno-occlusive dysfunction. ( 23219214 )
2013
14
On call. I have read several news reports that claim finasteride, which I take for my prostate problem, can cause permanent impotence. Should I be concerned? ( 23807950 )
2013
15
Office-based management of impotence and Peyronie's disease. ( 24182973 )
2013
16
The role of interventional radiology in the diagnosis and management of male impotence. ( 23188557 )
2013
17
Lue TF, Zeineh SJ, Scmidt RA and Tanagho EA--Neuroanatomy of penile erection: its relevance to iatrogenic impotence. 1984. ( 21284826 )
2011
18
The impotence of price controls: failed attempts to constrain pharmaceutical expenditures in Greece. ( 20884073 )
2011
19
Treatment of diabetic impotence with umbilical cord blood stem cell intracavernosal transplant: preliminary report of 7 cases. ( 20565373 )
2010
20
Humanity, what will you choose-ominous impotence or omnipotence? ( 21191535 )
2010
21
Transurethral resection of the prostate stands accused of causing impotence in patients: should it be found culpable? ( 20394617 )
2010
22
The role of Doppler ultrasound in the diagnosis of vasculogenic impotence. ( 21341552 )
2010
23
Superoxide dismutase analog (Tempol: 4-hydroxy-2, 2, 6, 6-tetramethylpiperidine 1-oxyl) treatment restores erectile function in diabetes-induced impotence. ( 19554009 )
2009
24
Nocturnal erections, differential diagnosis of impotence, and diabetes. I Karacan, FB Scott, PJ Salis, SL Attia, JC Ware, A Altinel, and RL Williams. ( 19215613 )
2009
25
Further experience with an operation for the cure of certain types of impotence. O.S. Lowsley, and A. Rueda. ( 19682228 )
2009
26
Impotence in the 18th and 19th century: concepts of etiology and approaches to therapy. ( 20013735 )
2009
27
Is intracavernous injection of papaverine a reliable screening test for vascular impotence? J. Buvat, M. Herbaut-Buvat, J.L. Dehaene, and A. Lemaire. ( 20092548 )
2009
28
Transient impotence after transrectal ultrasound-guided prostate biopsy. ( 17924579 )
2008
29
Decreased ecto-NTPDase1/CD39 activity leads to desensitization of P2 purinoceptors regulating tonus of corpora cavernosa in impotent men with endothelial dysfunction. ( 18600538 )
2008
30
Impotence and suing for sex in eighteenth-century England. ( 18342192 )
2008
31
Cavernosal alpha-blockade: a new technique for investigating and treating erectile impotence by GS Brindley. ( 18774989 )
2008
32
Alternate-day tadalafil in the management of honeymoon impotence. ( 18208502 )
2008
33
Management of erectile impotence: use of inflatable prosthesis. ( 19006495 )
2008
34
Direct arterial anastomosis on corpora cavernosal penis in the therapy of erectile impotence. V. Michal, R. Kramar, j. Pospichal, and L. Hejhal. 1973. ( 18439152 )
2008
35
Impotence and libido in Arabic medical literature. ( 18792558 )
2008
36
Vasculogenic impotence as a symptom in late-onset Buerger's disease. ( 17486572 )
2007
37
Curing prostate cancer--without surgery. Combo radiation therapies enable prostate retention, low risk of incontinence and impotence. ( 17441276 )
2007
38
Thalidomide induced impotence in male hematology patients: a common but ignored complication? ( 18024384 )
2007
39
The impotence of being important--reflections on leadership. ( 17548855 )
2007
40
Management of honeymoon impotence. ( 16490033 )
2006
41
Restoration of satisfying sex for a castrated cancer patient with complete impotence: a case study. ( 16959662 )
2006
42
Relationship between nocturnal penile tumescence parameters, International Index of Erectile Function symptom scores and sildenafil responses1This paper was presented at the 6th Congress of the International Society of Sexual and Impotence Research, Buenos Aires, Argentina, 17-21 October 2004. ( 17130103 )
2006
43
On call. Whenever I ride my bike for more than an hour or so, I notice numbness in my penis. I know that can lead to impotence, so I've stopped taking long rides. But now I see some policemen in my town patrolling on bikes all day long. Will they end up with problems? ( 17288024 )
2006
44
Corpus cavernosum from men with vasculogenic impotence is partially resistant to adenosine relaxation due to endothelial A(2B) receptor dysfunction. ( 16837560 )
2006
45
An herbal remedy for impotence: more than was bargained for. ( 17050803 )
2006
46
HMG CoA reductase inhibitors and impotence: two case series from the Spanish and French drug monitoring systems. ( 16454541 )
2006
47
Enhanced thromboxane receptor-mediated responses and impaired endothelium-dependent relaxation in human corpus cavernosum from diabetic impotent men: role of protein kinase C activity. ( 16888082 )
2006
48
Impotence in the XVIII-XIX century as described by Gian Pietro Fusanacci and Tommaso Eduardo Beatty. ( 16874715 )
2006
49
The impotence of cumulative effects assessment in Canada: ailments and ideas for redeployment. ( 16362488 )
2006
50
Tobacco education: emphasizing impotence as a consequence of smoking. ( 17158700 )
2006

Variations for Impotence

Expression for Impotence

Search GEO for disease gene expression data for Impotence.

Pathways for Impotence

Pathways related to Impotence according to GeneCards Suite gene sharing:

(show all 15)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.08 CAV1 KCNMA1 KNG1 NOS1 NOS2 NOS3
2
Show member pathways
12.7 CAV1 NOS1 NOS2 NOS3 PDE3A
3
Show member pathways
11.91 KCNMA1 NOS1 NOS2 NOS3 PDE3A PDE5A
4 11.72 EDN1 NOS2 NOS3
5
Show member pathways
11.6 ACE KNG1 NOS3
6 11.5 ACE KCNMA1 PDE3A
7
Show member pathways
11.44 NOS1 NOS2 NOS3
8
Show member pathways
11.38 ALDH7A1 NOS1 NOS2 NOS3
9
Show member pathways
11.26 NOS1 NOS2 NOS3
10
Show member pathways
11.14 NOS1 NOS2 NOS3
11 11.06 NOS1 NOS2 NOS3
12 10.92 NOS1 NOS2 NOS3
13
Show member pathways
10.72 KCNMA1 NOS1 NOS2 NOS3 PDE3A PDE5A
14 10.37 NOS1 NOS2 NOS3 PDE5A
15 10.34 NOS1 NOS2 NOS3

GO Terms for Impotence

Cellular components related to Impotence according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 caveola GO:0005901 8.92 CAV1 KCNMA1 NOS1 NOS3

Biological processes related to Impotence according to GeneCards Suite gene sharing:

(show all 31)
id Name GO ID Score Top Affiliating Genes
1 response to drug GO:0042493 9.93 EDN1 PDE3A PRL SRD5A1
2 cell redox homeostasis GO:0045454 9.76 NOS1 NOS2 NOS3
3 regulation of blood pressure GO:0008217 9.74 ACE EDN1 NOS3
4 cellular response to transforming growth factor beta stimulus GO:0071560 9.72 CAV1 EDN1 PDE3A
5 regulation of vasoconstriction GO:0019229 9.65 ACE EDN1
6 regulation of sodium ion transport GO:0002028 9.65 NOS1 NOS3
7 negative regulation of blood pressure GO:0045776 9.65 NOS1 NOS2 NOS3
8 response to hypoxia GO:0001666 9.65 CAV1 EDN1 KCNMA1 NOS1 NOS2
9 cellular response to peptide hormone stimulus GO:0071375 9.64 CAV1 EDN1
10 vasoconstriction GO:0042310 9.64 CAV1 EDN1
11 positive regulation of cardiac muscle hypertrophy GO:0010613 9.63 EDN1 PDE5A
12 androgen metabolic process GO:0008209 9.62 CYP3A4 SRD5A1
13 negative regulation of blood coagulation GO:0030195 9.62 EDN1 KNG1
14 negative regulation of calcium ion transport GO:0051926 9.61 NOS1 NOS3
15 exogenous drug catabolic process GO:0042738 9.61 CYP3A4 NOS1
16 negative regulation of potassium ion transport GO:0043267 9.6 NOS1 NOS3
17 multicellular organismal response to stress GO:0033555 9.59 NOS1 PRL
18 body fluid secretion GO:0007589 9.58 EDN1 VIP
19 vasodilation GO:0042311 9.58 KNG1 NOS1 NOS3
20 negative regulation of hydrolase activity GO:0051346 9.56 NOS1 NOS3
21 nitric oxide mediated signal transduction GO:0007263 9.54 NOS1 NOS2 NOS3
22 regulation of systemic arterial blood pressure by endothelin GO:0003100 9.52 EDN1 NOS3
23 diterpenoid metabolic process GO:0016101 9.51 PDE3A SRD5A1
24 regulation of blood vessel size GO:0050880 9.5 EDN1 KNG1 NOS3
25 peptidyl-cysteine S-nitrosylation GO:0018119 9.49 NOS1 NOS2
26 regulation of the force of heart contraction by chemical signal GO:0003057 9.46 CAV1 NOS3
27 positive regulation of oocyte development GO:0060282 9.43 PDE3A PDE5A
28 nitric oxide biosynthetic process GO:0006809 9.33 NOS1 NOS2 NOS3
29 positive regulation of guanylate cyclase activity GO:0031284 9.13 NOS1 NOS2 NOS3
30 arginine catabolic process GO:0006527 8.8 NOS1 NOS2 NOS3
31 oxidation-reduction process GO:0055114 10.01 ALDH7A1 CYP3A4 NOS1 NOS2 NOS3 SRD5A1

Molecular functions related to Impotence according to GeneCards Suite gene sharing:

(show all 14)
id Name GO ID Score Top Affiliating Genes
1 oxidoreductase activity GO:0016491 9.91 ALDH7A1 CYP3A4 NOS1 NOS2 NOS3 SRD5A1
2 iron ion binding GO:0005506 9.76 CYP3A4 NOS1 NOS2 NOS3
3 heme binding GO:0020037 9.71 CYP3A4 NOS1 NOS2 NOS3
4 hormone activity GO:0005179 9.7 EDN1 PRL VIP
5 flavin adenine dinucleotide binding GO:0050660 9.67 NOS1 NOS2 NOS3
6 3,5-cyclic-nucleotide phosphodiesterase activity GO:0004114 9.54 PDE3A PDE5A
7 NADP binding GO:0050661 9.54 NOS1 NOS2 NOS3
8 3,5-cyclic-GMP phosphodiesterase activity GO:0047555 9.51 PDE3A PDE5A
9 FMN binding GO:0010181 9.5 NOS1 NOS2 NOS3
10 cadmium ion binding GO:0046870 9.48 NOS1 NOS3
11 arginine binding GO:0034618 9.43 NOS1 NOS2 NOS3
12 NADPH-hemoprotein reductase activity GO:0003958 9.33 NOS1 NOS2 NOS3
13 tetrahydrobiopterin binding GO:0034617 9.13 NOS1 NOS2 NOS3
14 nitric-oxide synthase activity GO:0004517 8.8 NOS1 NOS2 NOS3

Sources for Impotence

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....